<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Renal and metabolic complications of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lysis during 46 episodes of remission induction chemotherapy were reviewed in 37 patients with American Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002157'>Azotemia</z:hpo> occurred in 14 patients, preceding chemotherapy in eight </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of these patients had <z:e sem="disease" ids="C0000735" disease_type="Neoplastic Process" abbrv="">abdominal tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Pretreatment <z:hpo ids='HP_0002157'>azotemia</z:hpo> was associated with elevated lactic dehydrogenase (LDH) and <z:chebi fb="3" ids="27226">uric acid</z:chebi> levels, and sometimes extrinsic <z:hpo ids='HP_0006000'>ureteral obstruction</z:hpo> by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients required dialysis for <z:chebi fb="3" ids="27226">uric acid</z:chebi> <z:hpo ids='HP_0000112'>nephropathy</z:hpo> before chemotherapy was initiated </plain></SENT>
<SENT sid="5" pm="."><plain>Following chemotherapy, major complications of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lysis (<z:hpo ids='HP_0002149'>hyperuricemia</z:hpo>, <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> and <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo>) were associated with very large <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, high LDH levels and inadequate urinary output </plain></SENT>
<SENT sid="6" pm="."><plain>In patients undergoing <z:mp ids='MP_0001762'>diuresis</z:mp> and receiving <z:chebi fb="0" ids="40279">allopurinol</z:chebi>, <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> or <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> developed infrequently unless concomitant <z:hpo ids='HP_0000083'>renal failure</z:hpo> ensued </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002905'>Hyperphosphatemia</z:hpo>, which occurred only after chemotherapy, developed in 10 of 32 (31 per cent) nonazotemic and in <z:hpo ids='HP_0000001'>all</z:hpo> azotemic patients </plain></SENT>
<SENT sid="8" pm="."><plain>Hemodialysis was required in three post-treatment patients for control of <z:hpo ids='HP_0002157'>azotemia</z:hpo>, <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo>, <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo> and/or <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Because of the potential for <z:hpo ids='HP_0000083'>renal failure</z:hpo> caused by precipitation of phosphate, severe <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo> is an additional criterion for dialysis in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> </plain></SENT>
</text></document>